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ABSTRACT
The recurrent V617F mutation in JAK2 (JAK2V617F) has emerged as the primary 
contributor to the pathogenesis of myeloproliferative neoplasms (MPN). However, the 
lack of complete response in most patients treated with the JAK1/2 inhibitor, ruxolitinib, 
indicates the need for identifying pathways that cooperate with JAK2. Activated 
JAK2 was found to be associated with the insulin receptor substrate 2 (IRS2) in non-
hematological cells. We identified JAK2/IRS2 binding in JAK2V617F HEL cells, but not in 
the JAK2WT U937 cell line. In HEL cells, IRS2 silencing decreased STAT5 phosphorylation, 
reduced cell viability and increased apoptosis; these effects were enhanced when IRS2 
silencing was combined with ruxolitinib. In U937 cells, IRS2 silencing neither reduced 
cell viability nor induced apoptosis. IRS1/2 pharmacological inhibition in primary 
MPN samples reduced cell viability in JAK2V617F-positive but not JAK2WT specimens; 
combination with ruxolitinib had additive effects. IRS2 expression was significantly 
higher in CD34+ cells from essential thrombocythemia patients compared to healthy 
donors, and in JAK2V617F MPN patients when compared to JAK2WT. Our data indicate that 
IRS2 is a binding partner of JAK2V617F in MPN. IRS2 contributes to increased cell viability 
and reduced apoptosis in JAK2-mutated cells. Combined pharmacological inhibition of 
IRS2 and JAK2 may have a potential clinical application in MPN.
INTRODUCTION
Chronic myeloproliferative neoplasms (MPN) are 
characterized by clonal defects that result in increased 
myeloid proliferation with preserved terminal differentiation 
[1]. The identification of a recurrent mutation in the tyrosine 
kinase Janus kinase 2 (JAK2V617F) in most patients with 
primary myelofibrosis (PMF), polycythemia vera (PV) 
and essential thrombocythemia (ET) suggest a potential 
common main cause of disease development [2, 3]. 
However, the description of other recurrent mutations, the 
evidence that MPN patients can respond to JAK2 inhibitors 
regardless of JAK2 mutation status, and the knowledge that 
many receptors and substrates may lead to the activation 
of the JAK/STAT, MAPK and PI3K/AKT/mTOR pathways 
through mechanisms other than the JAK2 pathway suggest 
that other interacting proteins may be involved in the 
pathophysiology of these diseases [4, 5].
In non-hematological cells, previous studies have 
reported that JAK2 can associate with the insulin receptor 
substrate 2 (IRS2). JAK2 co-immunoprecipitates with 
IRS2 following angiotensin II stimulation in the left 
ventricle of rats [6, 7], and upon leptin stimulation in 
the rat liver [8]. IRS2 is a 180kDa adapter protein that 
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was described in 1995 as being the equivalent to the 
4PS protein, initially identified as a substrate of the IL4 
receptor-associated tyrosine kinase in myeloid cells [9]. 
IRS2 associates with the p85 subunit of PI3K and with 
GRB2 and mediates mitogenic and antiapoptotic signaling 
from IR, IGF1R, EPOR, MPL, VEGF, insulin, leptin, 
GH, interleukins and IFNα/β/γ, which can influence the 
proliferation of neoplastic cells [7, 9–17]. During the 
erythroid maturation of normal and PV cells, insulin 
and IGF1 induce cell signaling through IRS1 and IRS2 
phosphorylation [18, 19]. IRS2 expression is higher 
in aggressive, metastatic human breast carcinoma cell 
lines [16], and mammary tumor cells that are deficient 
for IRS2 expression are significantly more sensitive to 
apoptotic stimuli, such as serum deprivation [16, 20, 21]. 
We have previously identified IRS2 phosphorylation to 
be upregulated during hematopoietic cell differentiation 
[22], although the functional role of IRS2 in hematopoietic 
neoplasms has not yet been addressed.
We hypothesized that IRS2 could participate in the 
activation of crucial signaling pathways in MPN via direct 
binding with JAK2 or through alternative mechanisms. In 
this study, we aimed to evaluate JAK2/IRS2 association and 
to describe the function of IRS2 in cell viability and apoptosis 
using cell lines and primary samples from MPN patients 
harboring wild-type or mutant JAK2. IRS2 mRNA expression 
levels were investigated in primary CD34+ cells from healthy 
donors and patients with MPN; IRS2 mRNA expression was 
compared between these groups and among MPN patients 
stratified according to JAK2 and CALR mutational status.
RESULTS
IRS2 is constitutively associated with JAK2 in 
HEL cells
Leukemia cell lines harboring the JAK2V617F 
mutation (HEL) or JAK2WT (U937, NB4, HL60) were 
used for immunoprecipitation and immunoblotting with 
anti-IRS2 and anti-JAK2 antibodies. Immunoprecipitation 
analysis revealed that JAK2 binds to IRS2 in HEL 
JAK2V617F cells, but not in U937, NB4 and HL60 JAK2WT 
cell lines (Figure 1A). Similarly, colocalization of IRS2 
and JAK2 by confocal microscopy was higher in HEL 
cells in comparison to U937 and NB4 cells (Figure 1B; 
Supplementary Figure S1). JAK2 and IRS2 protein 
expressions in these cell lines are illustrated in Figure 1C.
Ruxolitinib decreases IRS2 phosphorylation in 
JAK2V617F cells
To verify the effects of ruxolitinib treatment on 
IRS2 phosphorylation and downstream pathways in 
cells expressing wild-type or mutant JAK2, HEL and 
Figure 1: IRS2 associates with JAK2 in HEL cells. A. Immunoprecipitation (IP) and immunoblotting (IB) with anti-IRS2 and 
JAK2 antibodies showed a constitutive association between IRS2 and JAK2 in HEL cells harboring the JAK2V617F mutation, but not in 
JAK2WT cell lines U937, NB4 and HL60. Isotype IgG antibody was used as a negative control of the immunoprecipitation; total cell extracts 
were used as positive controls for immunoblotting. Blots were cropped to improve the clarity of the figure and retain important bands. 
B. Confocal analysis of HEL, U937 and NB4 cells displaying JAK2 (green), IRS2 (red) and DAPI (blue) staining; MERGE shows the 
overlapped images. Colocalization analysis was performed with the “colocalization finder” plug-in of Image J NIH software, and shows 
merged images of JAK2 and IRS2, with colocalized points in white. The correlation coefficient (r) values are indicated. C. Immunoblotting 
(IB) with anti-IRS2 and JAK2 antibodies showed high IRS2 and JAK2 expression in HEL, U937, NB4 and HL60 cell lines.
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U937 cells treated with increasing concentrations of 
ruxolitinib for 6h were tested for total and phospho-
proteins by immunoblotting with specific antibodies. In 
HEL cells, ruxolitinib treatment resulted in decreased 
phosphorylation of IRS2, JAK2, STAT3, STAT5, ERK 
and P70S6K, but no changes were observed in phospho-
AKT levels (Figure 2A). In contrast, U937 cells showed 
little to no phosphorylated IRS2 and STAT3 even in 
the absence of ruxolitinib treatment, but demonstrated 
reduced JAK2, STAT5, ERK and P70S6K phosphorylation 
upon ruxolitinib administration (Figure 2B). NB4 cells, 
which also harbor wild-type JAK2, showed neither 
constitutive phosphorylation of JAK2 nor any reduction in 
downstream signaling proteins upon ruxolitinib treatment 
(Supplementary Figure S2). Given these findings, HEL 
and U937 cells were selected for further study as models 
of JAK2V617F and JAK2WT signaling.
IRS2 silencing decreases STAT5 phosphorylation 
in HEL cells
To investigate the function of IRS2 in wild-
type and mutant JAK2 cells, HEL and U937 cells were 
efficiently silenced for IRS2 through stable transduction 
with lentiviral constructs encoding shRNA targeting 
IRS2 (shIRS2) or a shRNA targeting a non-specific 
control sequence (shControl), as verified by qPCR and 
western blotting (Figure 3A–3B). To determine the 
combined effects of IRS2 inhibition and ruxolitinib 
treatment on JAK/STAT, PI3K/AKT/mTOR and MAPK 
signaling, shControl and shIRS2 cells were treated 
with DMSO or ruxolitinib (100 or 300nM) for 48h, and 
submitted to immunoblotting with specific antibodies. 
In HEL cells, IRS2 silencing alone was able to induce 
decreased phosphorylation of STAT5 and increased 
phospho-ERK levels. Ruxolitinib downregulated JAK/
STAT (decreased phosphorylation of JAK2, STAT3 and 
STAT5) and MAPK signaling (decreased phosphorylation 
of ERK and P70S6K), but did not modulate AKT 
phosphorylation in HEL cells (Figure 3A). In JAK2WT 
U937 cells, however, while IRS2 silencing did not 
change STAT5 phosphorylation, increased phospho-ERK 
levels were observed (Figure 3B). The individual effects 
of IRS2 silencing were not observed in cells submitted 
to ruxolitinib 300nM treatment, since such treatment 
results in near complete inhibition of phospho-STAT5 and 
phospho-ERK by 48h of exposure (Figure 3A–3B).
IRS2 silencing decreases cell viability and 
potentiates the effect of ruxolitinib in JAK2V617F 
cells
To evaluate the role of IRS2 on cell viability and 
clonogenicity, cells were silenced for IRS2 and submitted 
to MTT (methylthiazole tetrazolium) or colony formation 
assays, respectively. To assess the combined effects of 
Figure 2: Ruxolitinib decreases IRS2 phosphorylation in JAK2V617F cells. Total cell extracts of A. JAK2V617F HEL cells or 
B. JAK2WT U937 cells treated with different doses of ruxolitinib for 6h were submitted to immunoblotting (IB) analysis with anti-IRS2, 
anti-phosphotyrosine, and antibodies to detect downstream proteins. The asterisk (*) indicates HEL cells used as a positive control along 
with U937 cells. Membranes were re-probed with the antibody for detection of the respective total and phospho-protein, and developed 
with the ECLTM Western Blot Analysis System. Blots were cropped to improve the clarity of the figure and retain important bands.
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IRS2 knockdown and JAK1/2 inhibition, shIRS2 or 
shControl cells were treated with ruxolitinib (100 and 
300nM) or DMSO for 48h (cell viability) or 8 days 
(colony formation). HEL cell viability and clonogenicity 
were significantly inhibited by IRS2 silencing (p ≤.01), 
and these effects were enhanced when IRS2 silencing 
was combined with ruxolitinib exposure (all p ≤.02) 
(Figure 4A–4B). In U937 cells, IRS2 silencing had no 
effects on cell viability and clonogenicity; ruxolitinib did 
not significantly suppress cell viability, but decreased the 
clonogenicity of these cells (Figure 4C–4D), likely due to 
the time of drug exposure necessary for each assay.
IRS2 silencing induces apoptosis and potentiates 
the effects of ruxolitinib in HEL cells
IRS2 silencing significantly induced apoptosis 
and potentiated the effects of ruxolitinib treatment 
in HEL cells (all p ≤.01) (Figure 5A). Consistent 
with this, increased caspase 3 cleavage was observed 
by immunoblotting in shIRS2 cells, with greater 
levels observed upon additional ruxolitinib treatment 
(Figure 5B). However, in U937 cells, IRS2 silencing 
alone or associated with ruxolitinib did not affect 
apoptosis, as assessed by Annexin V+/PI- and 
immunoblotting with anti-cleaved caspase 3 antibodies 
(all p ≥.05). Of note, ruxolitinib did not induce apoptosis 
in U937 cells (Figure 5C–5D).
Increased IRS2 mRNA expression in patients 
harboring the JAK2V617F mutation
IRS2 mRNA levels were evaluated in peripheral 
blood CD34+ cells from healthy donors and patients with 
MPN. Significantly increased IRS2 mRNA expression 
was observed in patients with ET when compared to 
healthy donors (0.35 [0.08-2.16] versus 0.18[0.00-2.29]; 
p =.03). A slight, although not statistically significant, 
increase in IRS2 mRNA expression was found in 
PV (0.36 [0.00-5.65]) and PMF (0.31 [0.00-2.16]) 
Figure 3: IRS2 silencing decreases STAT5 phosphorylation in HEL (JAK2V617F) cells, but not in U937 (JAK2WT) cells. 
A. HEL cells or B. U937 cells were transduced with lentivirus-mediated shRNA control (shControl) or IRS2 (shIRS2). IRS2 mRNA and 
protein expression in shIRS2 cells relative to the shControl cells (upper panel). Western blot analysis for total and phospho-proteins JAK2, 
STAT3, STAT5, ERK, AKT and P70S6K in total cell extracts of shControl and shIRS2 HEL or U937 cells treated with ruxolitinib (100 or 
300nM) or DMSO for 48h (lower panel). The antibodies used for immunoblotting (IB) are indicated; membranes were reprobed with the 
antibody for detection of the respective total and phospho-protein or actin, and developed with the ECL Western Blot Analysis System. 
Blots were cropped to improve the clarity of the figure and retain important bands.
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patients when compared to healthy donors (Figure 6A). 
Significantly higher levels of IRS2 mRNA expression 
were also observed in JAK2V617F patients when compared 
to JAK2WT (0.46 [0.00-5.65] versus 0.29 [0.00-0.83]; 
p<.001) (Figure 6B). This difference remained significant 
when comparing JAK2V617F and JAK2WT patients in 
individual groups (ET, PMF) (p ≤.02). Despite the low 
IRS2 mRNA expression in JAK2WT PV patients, the 
number of wild-type samples was excessively small 
(n=2) for statistical analysis (Supplementary Table S3). 
IRS2 mRNA expression was significantly lower in 
CALRexon9indel_MUT patients compared to CALRWT (0.30 
[0.00-0.82] versus 0.42 [0.00-5.65]; p=.02) (Figure 6C); 
this difference in IRS2 expression would be expected 
since, in this cohort, JAK2V617F and CALR mutations 
were mutually exclusive, and CALRMUT patients 
represent the JAK2WT patients.
IRS2 inhibition decreases cell viability in 
JAK2V617F primary cells and potentiates the 
efficacy of ruxolitinib
To evaluate the combined effects of IRS2 and 
JAK1/2 pharmacological inhibition in MPN primary 
cells, mononuclear cells isolated from peripheral blood 
samples obtained from four JAK2V617F and three JAK2WT 
MPN patients were submitted to ex vivo treatment with 
the IRS/IGF1R inhibitor NT157, ruxolitinib, or both 
drugs combined. Six of the seven patients included in 
the ex vivo experiments were MPL and CALR wild type; 
one patient with ET (sample #6) who had wild type JAK2 
and CALR harbored a MPLW515L mutation. In JAK2V617F-
positive primary cells from PMF and PV patients (samples 
#1 to #4), a reduced cell viability following NT157 and 
ruxolitinib exposure alone was observed, and the combined 
treatment with both inhibitors resulted in cumulative effects 
Figure 4: IRS2 silencing reduces cell viability and colony formation, and potentiates the effects of ruxolitinib in HEL 
cells. A. Cell viability was determined by methylthiazole tetrazolium (MTT) assay after 48h of incubation of shIRS2 HEL cells and 
normalized by the corresponding shControl HEL cells. Results are shown as mean ± SD of eight independent experiments; Mann–Whitney 
test. B. Colonies containing viable cells were detected by MTT after 8 days of culture of shIRS2 HEL cells and normalized by the 
corresponding shControl HEL cells. The percentage of colonies relative to controls are shown in the bar graph as mean ± SD of twelve 
independent experiments; Student's t-test. The assays were performed in the presence of ruxolitinib (100 or 300mM) or DMSO, as indicated. 
C. U937 cells stably-transduced with lentivirus-mediated shRNA control (shControl) or IRS2 (shIRS2) were submitted to MTT assay or 
D. colony forming assay, as indicated. All conditions were tested in at least eight independent experiments, and no statistically significant 
difference was observed for U937 cells.
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(Figures 7A). In JAK2WT primary cells (samples #5 to #7), 
NT157 reduced cell viability only in sample #6 (ET patient, 
MPLW515L-mutated), while ruxolitinib reduced cell viability 
only in sample #7 (PMF patient). Of note, no combined 
effect of NT157 plus ruxolitinib was noted in JAK2WT 
samples (Figures 7B).
DISCUSSION
IRS2 mediates downstream signaling from 
EPOR and MPL in hematopoietic cells [14, 23] and 
associates with JAK2 upon an extrinsic stimulus in non-
hematological cells [6–8]. We hypothesized that the 
constitutive activation of JAK2 induced by the V617F 
mutation itself could lead to JAK2/IRS2 binding, and that 
this protein association could participate in the malignant 
phenotype of JAK2V617F-positive MPN patients. We herein 
describe that IRS2 is a binding partner of JAK2 in the 
human JAK2V617F-positive HEL cell line, an association 
which was not observed in U937, NB4 and HL60 cells 
(JAK2WT). The lack of the JAK2/IRS2 association in 
U937, NB4 and HL60 cells corroborates the hypothesis 
that activated JAK2 is crucial for IRS2 recruitment.
Erythropoeitin induces IRS2 upregulation in primary 
erythroblasts and in human acute myeloid leukemia cells 
UT7 [14, 24]. Interestingly, IRS2 can associate directly 
with both EPOR [14] and JAK2 [6]. JAK2 tyrosine 
phosphorylation by EPOR or by other mechanisms leads 
to the recruitment of SH2 and PTB domain-containing 
proteins and initiates major tyrosine phosphorylation [25, 
26]. As such, the IRS2 PTB domain may be involved in the 
JAK2/IRS2 association in JAK2V617F cells. Alternatively, 
Duan et al. [27] demonstrated that the SH2B adaptor 
protein binds simultaneously to both JAK2 and IRS2, 
promoting the formation of a JAK2/SH2B/IRS2 tertiary 
complex and the subsequent tyrosine phosphorylation of 
IRS2 by JAK2. Leptin has been shown to induce JAK2/
IRS2 association in HEK293 cells expressing leptin 
Figure 5: IRS2 silencing induces apoptosis and has cumulative effects with ruxolitinib in HEL cells. A. Apoptosis was 
detected by flow cytometry in HEL cells transduced with shControl and shIRS2 using Annexin V+/PI- staining method and a representative 
dot plot is illustrated. Bar graphs are shown as mean ± SD of eight independent experiments; Student's t-test. The assays were performed 
in the presence of ruxolitinib (100 and 300mM) or DMSO for 48h, as indicated. B. All conditions were submitted to imunoblotting (IB) 
analysis for cleaved caspase 3, and a representative experiment is shown. Membranes were reprobed with the antibody for detection 
of actin, and developed with the ECL Western Blot Analysis System. Blots were cropped to improve the clarity of the figure and retain 
important bands. C. shControl or shIRS2 U937 cells treated with DMSO only or ruxolitinib (100 or 300nM) for 48h were submitted to 
Annexin V/PI staining and D. imunoblotting for cleaved caspase 3, as indicated. All conditions were tested in at least eight independent 
experiments, and no statistically significant difference in apoptosis was observed for U937 cells; no cleaved caspase 3 was observed in any 
condition. The asterisk (*) indicates ruxolitinib-treated HEL cells used as a positive control for apoptosis along with U937 cells.
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Figure 6: Increased IRS2 mRNA levels in CD34+ cells from JAK2V617F-positive myeloproliferative neoplasm patients. 
A. qPCR analysis of IRS2 mRNA expression in peripheral blood (PB) CD34+ cells from healthy donors and patients with the diagnosis of 
essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF), and stratified by B. JAK2V617F or C. CALR 
exon 9 mutational status. Horizontal lines indicate medians. The number of subjects and the p values (Mann–Whitney test) are indicated.
Figure 7: IRS2 pharmacological inhibition decreases cell viability in JAK2V617F myeloproliferative neoplasm primary 
cells and has cumulative effects with ruxolitinib. Cell viability was determined by methanethiosulfonate (MTS)-based assay 
(patients #1 to #3, #5 and #6) or by methylthiazole tetrazolium (MTT) (patients #4 and #7) after 72h of incubation of JAK2V617F A. 
or JAKWT B. myeloproliferative neoplasms (MPN) patients' peripheral blood mononuclear cells with different concentrations of NT157 
(IRS1/2 inhibitor) or ruxolitinib (JAK1/2 inhibitor) alone or in combination, as indicated. All conditions were tested in triplicate. Data 
were normalized to the mean percent of the untreated control wells. PMF: primary myelofibrosis; PV: polycythemia vera; ET: essential 
thrombocythemia.
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receptor only in the presence of SH2B, and leptin was 
able to induce neither JAK2 nor IRS2 activation in SH2B-
/- mice [28], indicating that an adaptor protein may also 
participate in the JAK2/IRS2 binding.
We herein demonstrated that IRS2 phosphorylation 
is increased in HEL cells, when compared to U937 cells. 
IRS2 gene expression is also higher in CD34+ cells from 
patients with ET, when compared to healthy donors, and 
from patients with JAK2V617F MPN compared to JAK2WT 
patients, indicating that the JAK2V617F mutation is associated 
with increased IRS2 expression. IRS2 lentivirus-mediated 
silencing reduced cell viability and clonogenicity and 
increased apoptosis in HEL cells (JAK2V617F), but not 
in U937 cells (JAK2WT). This might be explained by the 
significantly diminished STAT5 tyrosine phosphorylation 
seen in IRS2-silenced HEL cells. Although phospho-STAT5 
was reduced by the JAK1/2 specific inhibitor ruxolitinib, 
IRS2 silencing alone significantly downregulated STAT5 
activation, suggesting that, in HEL cells, STAT5 may be 
activated both by an IRS2-dependent/JAK2-independent 
and JAK2-dependent mechanism. This could explain the 
additive effects observed in IRS2-silenced/ ruxolitinib-
treated cells. Although STAT5 is a classical downstream 
protein activated by JAK2, insulin can also induce STAT5 
activation in a JAK2-independent manner [29]. In the 
rhabdomyosarcoma cell line Kym-1, an insulin receptor 
kinase inhibitor abolished the insulin-induced STAT5 
tyrosine phosphorylation, but this effect was not obtained 
with a JAK2 kinase inhibitor [29]. Recently, Schafranek 
and colleagues have also shown that the loss of STAT5 
activity, rather than JAK2, is critical for the irreversible 
induction of cell death in BCR-ABL-positive cells [30]. 
Since STAT5 activation decreases apoptosis [31–34] and 
induces malignant transformation and tumor progression 
[32, 35–38], the STAT5 downregulation promoted by IRS2 
inhibition may contribute to the reduced tumor proliferation 
and survival in HEL cells. Interestingly, IRS2 silencing 
resulted in increased phospho-ERK expression in both HEL 
and U937 cells, although IRS2 inhibition reduced survival 
only in HEL cells. These data suggest that the increased 
ERK phosphorylation induced by IRS2 silencing itself is 
not enough to induce the observed effects on cell survival. 
The mechanism of ERK phosphorylation and the biological 
consequence of this finding needs to be better clarified in 
future studies, although, at least in the cell models tested 
here, the biological effects of IRS2 inhibition seem to be 
independent of ERK phosphorylation status.
The insulin receptor substrates, as major mediators 
of downstream pathways involved in cell proliferation and 
survival, are important proteins for cancer pathogenesis 
[11, 16, 20, 21, 39, 40]. Pharmacological IRS inhibition 
was able to inhibit colony formation and cell migration 
of human melanoma [39] and prostate cancer cells [41]. 
Interestingly, however, no effects on the survival of 
normal melanocytes were observed [39]. Mammary tumor 
cells deficient for IRS2 expression are more sensitive to 
apoptotic stimuli [20]. We herein showed that the ex vivo 
treatment of JAK2V617F MPN primary cells with the IRS/
IGF1R inhibitor NT157 resulted in reduced cell viability 
and had cumulative effects with ruxolitinib. Interestingly, 
no evident modulation of cell viability was observed in 
JAK2WT primary cells following NT157 or ruxolitinib 
exposure alone or in combination, corroborating our 
findings that the constitutive activation of signaling 
pathways driven by JAK2V617F, including IRS2/JAK2 
binding, is necessary for the biological effects of IRS 
and JAK1/2 inhibitors. Taken together, these data support 
the hypothesis that IRS2 contributes to the malignant 
phenotype of JAK2V617F MPN.
Our data indicate that IRS2 is a binding partner 
of JAK2V617F and promotes cell survival in MPN. The 
additive effects of IRS2 silencing in inducing apoptosis 
observed upon co-treatment with ruxolitinib highlights the 
potential for use of IRS2 inhibitors in combination with 
JAK2 inhibitors in the treatment of these diseases. Future 
research using IRS2 inhibition in ex vivo studies, including 
a larger cohort of MPN patients, and in MPN animal 
models may help to predict the in vivo effectiveness and 
collateral effects of IRS2 inhibitors.
MATERIALS AND METHODS
Cell culture, ruxolitinib treatment and IRS2 
silencing
Human cell lines mutated for JAK2V617F (HEL) 
or wild-type for JAK2 (U937, NB4 and HL60) were 
used. HEL, U937 and HL60 cells were obtained from 
ATCC (Philadelphia, PA, USA), NB4 cells were kindly 
provided by Dr. Eduardo M. Rego (University of São 
Paulo, Brazil). Cell lines were tested and authenticated 
by STR matching analysis using the PowerPlex® 16 HS 
system (Promega, Madison, WI, USA ) and the ABI 3500 
Sequence Detector System (Applied Biosystems, Foster 
City, CA, USA); cells were tested in our laboratory before 
manuscript submission. Cells (2 × 105/mL) were incubated 
with ruxolitinib (Novartis Pharmaceuticals, Switzerland) 
or with DMSO for 6 or 48h.
Transduction of lentivirus
HEL and U937 cells were transduced with 
lentivirus-mediated shRNA nonspecific control (SC-
108080) or lentivirus-mediated shRNA targeting IRS2 
(SC-29378-V) from Santa Cruz Biotechnology (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) and named 
shControl and shIRS2 cells, respectively. Briefly, 2×105 
cells were transduced with lentiviral by spinoculation 
at multiplicity of infection equal to 4.0 and selected by 
puromycin (0.75μg/mL for HEL and 1.0μg/mL for U937 
cells). On day 21, cells were tested for IRS2 inhibition by 
qPCR and immunoblotting.
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Real-time quantitative PCR analysis
Cells were submitted to RNA extraction and assayed 
with cDNA (RevertAid H Minus First Strand cDNA 
Synthesis Kit; MBI Fermentas, St. Leon-Rot, Germany), 
SYBR Green Master Mix PCR (MBI Fermentas) and 
specific primers for IRS2 and HPRT (Supplementary 
Table S1). Quantitative PCR (qPCR) was performed 
with an ABI 7500 Sequence Detector System (Applied 
Biosystems). The relative gene expression was calculated 
using the equation, 2−ΔΔCT.
Immunoprecipitation and immunoblotting
Equal amounts of protein were used for total 
extracts or for immunoprecipitation with specific 
antibodies, followed by SDS-PAGE and Western blot 
analysis with the indicated antibodies (Supplementary 
Table S2) and ECL™ Western Blotting Analysis 
System (Amersham Pharmacia Biotech, UK Ltd., 
Buckinghamshire, UK). Blots were stripped and reprobed 
as necessary.
Confocal immunofluorescence microscopy
HEL, U937, and NB4 cells were grown on cover 
slips coated with poly-L-lysine (1mg/mL), fixed with 4% 
paraformaldehyde, permeabilized with 0.5% Triton X-PBS 
and blocked with 3% bovine serum albumin (BSA) PBS. 
Cells were then incubated overnight at 4°C with anti-
IRS2 or anti-JAK2 antibodies (1:200 in 1% BSA PBS), 
followed by incubation with secondary antibody (1:400 in 
1% BSA PBS) for 2h at room temperature. All incubations 
were followed by three 5min PBS washes. The slides 
were mounted in ProLong Gold Anti-Fade Mounting 
Medium with DAPI (Life Technologies, Carlsbad, USA). 
Images were generated using a confocal laser-scanning 
microscope (LSM 510, Carl Zeiss, Welwyn Garden City, 
UK). The “colocalization finder” plug in of Image J 
quantification software (U.S. National Institutes of Health, 
Bethesda, USA) was used for the analysis of JAK2 and 
IRS2 colocalization analysis.
Cell viability and colony forming assays
Cell viability was measured by methylthiazole 
tetrazolium (MTT) assay for HEL and U937 cells. A 
total of 5×104 ShControl or shIRS2 cells per well were 
plated in a 96-well plate in RPMI 10% FBS at different 
concentrations of ruxolitinib (100 or 300nM) or with 
DMSO for 48h. Briefly, 10μL of a 5mg/mL solution of 
MTT was added to the wells and incubated at 37°C for 
4h. The reaction was stopped by using 100μL of 0.1 N 
HCl in anhydrous isopropanol and was evaluated by 
measuring the absorbance at 570nm using an automated 
plate reader. Colony formation was carried out in 
semisolid methyl cellulose medium (0.5×103 cell/mL; 
MethoCult 4230; StemCell Technologies Inc., Vancouver, 
BC, Canada). Colonies were detected after 8 days of 
culture by adding 1mg/mL of MTT reagent and scored by 
Image J quantification software (US National Institutes 
of Health, Bethesda, MD, USA). For HEL and U937 
cell lines, shControl and shIRS2 cells were submitted to 
colony formation assay in the presence of ruxolitinib in 
two different concentrations (100 or 300nM) or DMSO 
for 8 days.
Assessment of apoptosis
HEL and U937 cells silenced for IRS2 and control 
cells were seeded on 12-well plates and treated with 
different concentrations of ruxolitinib (100 or 300nM) or 
DMSO for 48h. Cells were washed twice with ice cold 
PBS and resuspended in binding buffer containing 1μg/
mL PI and 1μg/mL FITC- or APC- labeled Annexin-V. 
All specimens were analyzed by flow cytometry using a 
FACSCalibur (Becton Dickinson, San Jose, CA, USA) 
after incubation for 15min at room temperature in a 
light-protected area. Ten thousand events were acquired 
for each sample. Cleaved-caspase 3 was evaluated by 
immunoblotting.
Primary patient samples
Peripheral blood (PB) samples were collected 
from 99 MPN patients from the outpatient clinic of the 
University of Campinas (median age 66, range 20-92; 
PV=30, ET=37, PMF=32) and from 28 healthy donors 
(median age 44, range 37-51) from the Blood Bank of 
the institution. Diagnoses were performed according to 
the 2008 World Health Organization criteria [1]. Among 
the patients, 64 were positive for the JAK2V617F mutation, 
25 had a CALR exon 9 indel mutation, 10 were negative 
for both mutations, and 2 patients had a JAK2V617F 
mutation but had not been tested for CALR mutations 
(due to lack of sample availability). Seventy-one patients 
were negative for W515L/K MPL mutations; twenty-
eight patients were not screened for MPL mutations 
due to the unavailability of good quality DNA samples; 
from those, only five cases were wild type for both 
JAK2 and CALR. This research was approved by the 
Institutional and National Review Board in accordance 
to the Helsinki Declaration; written informed consent 
was obtained from all subjects. Seventy-two out of 99 
patients were in regular use of hydroxyurea at the time 
of sampling; none had received additional chemotherapy 
or a JAK1/2 inhibitor before sampling. CD34+ cells were 
isolated from PB mononuclear cells by MIDI-MACS 
immunoaffinity columns (Miltenyi Biotec, USA) and 
>90% purity was verified by flow cytometry.
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Ex vivo drug combination treatment of primary 
patient cells
Patients were seen at the Oregon Health & Science 
University Center for Hematologic Malignancies 
(patients #1 to #3, #5 and #6) or at the Hematology and 
Hemotherapy Center of the University of Campinas 
(patients #4 and #7). Following informed consent, 
peripheral blood was collected and mononuclear cells 
were isolated by Ficoll-gradient centrifugation. Cells were 
resuspended in RPMI 1640 medium supplemented with 
10% FBS, L-glutamine, and penicillin/streptomycin and 
plated in 384-well plates (9000 cells/well) in triplicate 
in the presence of the JAK1/2 inhibitor ruxolitinib (0-
4000nM), the IRS/IGF1R inhibitor NT157 (0-4000nM; 
Axon MedChem, USA), or both inhibitors in combination 
at the indicated concentrations. Plates were cultured 
at 37°C for 72h, and absorbance was measured by a 
methanethiosulfonate (MTS)-based assay, according 
to the manufacturer’s protocol (CellTiter 96 AQueous 
One; Promega) for patients #1 to #3, #5 and #6, or by 
methylthiazole tetrazolium (MTT) assay for patients #4 
and #7. Data were normalized to the mean percent of the 
untreated control wells.
Statistical analysis
Statistical analyses were performed using GraphPad 
Instat 5 (GraphPad Software, USA). Shapiro–Wilk 
was used as a test of normality. For comparisons, an 
appropriate Student’s t-test or Mann–Whitney test was 
performed. A p value <.05 was considered as statistically 
significant.
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